Noradrenergic drugs may improve Alzheimer's symptoms, review finds

Studies suggest the agents may improve cognition and apathy but not memory

Commonly prescribed noradrenergic drugs such as methylphenidate could be repurposed to treat general cognitive symptoms and apathy in Alzheimer’s disease, neurology researchers suggest.

Results from a systematic review and meta-analysis of 19 clinical trials suggest that targeting noradrenergic dysfunction in affected patients could also have disease-modifying effects, they said.

“There is a strong rationale for further, targeted clinical trials of noradrenergic treatments in Alzheimer’s disease,” the